GlassScriptPhysician profile
Xylona Bibal
NPI 1699112169
$1,779.22
in general payments reported to CMS, 2019-2025
19 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $319 · 2022: $44.82 · 2023: $281 · 2024: $283 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671 · Education: $52.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.09 |
| Education | $52.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $807.33 | 2019-2024 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $149.01 | 2024-2025 | |
| Novo Nordisk INC | $102.86 | 2019-2025 | |
| Gilead Sciences, INC. | $89.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $79.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.97 | 2019-2024 | Jardiance |
| Pfizer INC. | $63.62 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $51.88 | 2019-2020 | |
| Astellas Pharma US INC | $43.73 | 2019 | |
| Allergan, INC. | $42.52 | 2019-2020 | |
| Janssen Biotech, INC. | $41.45 | 2019-2023 | Symtuza |
| Amgen INC. | $40.42 | 2023-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $37.18 | 2019-2020 | |
| Theratechnologies INC. | $36.71 | 2023 | Trogarzo, Egrifta |
| E.R. Squibb & Sons, L.L.C. | $29.44 | 2023 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $27.14 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $24.00 | 2019 | |
| Circassia INC. | $20.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xylona Bibal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.